Dynavax Technologies Corporation DVAX
Updated: 16 Jun 2026
No signal published yet
We already track Dynavax Technologies and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Dynavax Technologies Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Dynavax Technologies free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In February 2026, Sanofi completed its acquisition of Dynavax Technologies in an all-cash transaction valued at approximately $2.2 billion. The acquisition integrates Dynavax's commercial hepatitis B vaccine and its clinical-stage shingles vaccine candidate into Sanofi's global vaccine portfolio.
What Firelda Watch includes for Dynavax Technologies Corporation
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Dynavax Technologies Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Dynavax Technologies free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more